论文部分内容阅读
目的:观察不同剂量氟伐他汀早期治疗急性心肌梗死患者,对血清炎性因子、凝血4项的影响。方法:53例急性心肌梗死患者分为A、B2组。A组(27例)口服氟伐他汀40mg/d,B组(26例)口服氟伐他汀80mg/d,治疗前后分别测高敏C反应蛋白(hs-CRP)、可溶性白细胞分化抗原40配体(sCD40L)、基质金属蛋白酶-9(MMP-9)和凝血4项,随访3个月和6个月。结果:A和B组患者血清hs-CRP、sCD40L、MMP-9在治疗后3个月和6个月后均有明显下降(P<0.05),且B组较A组更明显。A组凝血酶原时间、部分凝血活酶、纤维蛋白原、凝血酶时间在治疗后3个月和6个月后无明显改变(P>0.05);B组凝血酶原时间、部分凝血活酶、凝血酶时间在治疗后3个月和6个月后明显延长,且纤维蛋白原明显降低(P<0.05)。结论:急性心肌梗死早期使用氟伐他汀可抑制患者炎性反应,且大剂量同时具有抗凝作用。
Objective: To observe the effect of different doses of fluvastatin on early treatment of patients with acute myocardial infarction, serum inflammatory factors, coagulation 4 items. Methods: 53 patients with acute myocardial infarction were divided into A and B2 groups. The patients in group A (27 cases) received fluvastatin 40 mg / d, group B (26 cases) received fluvastatin 80 mg / d, and the levels of hs-CRP and soluble ligand of ligand 40 sCD40L), matrix metalloproteinase-9 (MMP-9) and coagulation 4, followed up for 3 months and 6 months. Results: Serum levels of hs-CRP, sCD40L and MMP-9 in group A and group B were significantly decreased at 3 months and 6 months after treatment (P <0.05), and group B was more obvious than group A. The prothrombin time, partial thromboplastin, fibrinogen and thrombin time in group A were not changed at 3 months and 6 months after treatment (P> 0.05). The prothrombin time, partial thromboplastin Thrombin time was significantly prolonged 3 months and 6 months after treatment, and fibrinogen was significantly reduced (P <0.05). Conclusion: Fluvastatin can inhibit the inflammatory reaction in patients with acute myocardial infarction in the early stage, and the high dose of fluvastatin can anticoagulant at the same time.